Samuel Sanchez‐Rivera
University of Puerto Rico System(PR)
Publications by Year
Research Areas
Psoriasis: Treatment and Pathogenesis, Health Systems, Economic Evaluations, Quality of Life, Dermatology and Skin Diseases, Autoimmune Bullous Skin Diseases, Cytokine Signaling Pathways and Interactions
Most-Cited Works
- → A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial(2019)168 cited
- → A randomized phase 3b study evaluating the safety and efficacy of risankizumab in adult patients with moderate-to-severe plaque psoriasis with non-pustular palmoplantar involvement(2024)5 cited
- → A Phase 3b Study Evaluating Safety and Efficacy of Risankizumab in Adult Patients with Moderate-to-Severe Plaque Psoriasis with Palmoplantar (Non-Pustular) Involvement(2023)
- → 51675 Safety and efficacy of risankizumab in adult patients with moderate-to-severe plaque psoriasis with non-pustular palmoplantar involvement: changes in PPASI and PASI from Phase 3b IMMprint trial(2024)
- → Efficacité et tolérance du risankizumab chez les patients adultes atteints de psoriasis en plaques modéré à sévère avec atteintes palmo-plantaires non pustuleuses : variation du DLQI et obtention d’un score DLQI 0/1 dans l’étude de phase 3b IMMprint(2024)
- → Efficacité et tolérance du risankizumab chez les patients adultes atteints de psoriasis en plaques modéré à sévère avec atteintes palmo-plantaires non pustuleuses : variations des scores PPASI et PASI dans l’étude de phase 3b IMMprint(2024)
- → 51652 Safety and efficacy of risankizumab in adult patients with moderate to severe plaque psoriasis with non-pustular palmoplantar involvement: change in DLQI and achievement of DLQI 0/1 results from the Phase 3b IMMprint trial(2024)